In gene and cell therapy, RNP-mediated CRISPR gene editing is quickly emerging as the new norm. For many gene editing firms, GenScript has created hundreds of Cas9, Cas12a, Cas13a, MAD7, ABE, CBE, and prime editors. Additionally, GenScript has licensed a number of the Broad Institute's verified GMP and RUO Grade catalog items.
One stop solution
Catalog product
- Low-off-target Cas variations licensed from MIT
- Next-day Delivery
Guaranteed customer service
- Deliver in 2-4 weeks
- Guaranteed purity and yield
- Applicable to all Cas variants
- Flexible scale starts at 500 µg
GMP production
- Quick GMP Production in 6–9 Months
- Batch-to-Batch consistency
- Process development
Add-on service
- Platform for dedicated activity assay
- AI-driven enzyme design to enhance function
Highlights
- Guaranteed delivery
- Guaranteed yield and purity
- Industrial-leading Speed
- In as little as two weeks
- Activity assay development
- Developed a procedure using an internal sgRNA and DNA substrate
- Scale-up Capacity
- Track record of GMP projects
Service details
Guarantee package specification
Image Credit: GenScript
Source: GenScript
| |
Cas nuclease variants |
Base editor/Prime editor |
| Amount |
Guaranteed delivery of 500 ug, 1 mg, 5 mg, 10 mg, or 20 mg |
Guaranteed delivery of 500 ug, 1 mg, or 5 mg |
| Tag |
His tag |
| QC Standard |
- ≥90% purity by SDS-PAGE and SEC-HPLC
- Concentration: 1-10 mg/ml
- <10 EU /mg endotoxin
- Nuclease removal
|
| Timeline |
2-4 weeks |